- Sellas Life Sciences Group Inc Corporate Update Call TranscriptJan 03, 2024
- Sellas Life Sciences Group Inc Expert Panel Discussion TranscriptMay 30, 2023
- Sellas Life Sciences Group Inc to Host Key Opinion Leader Webinar TranscriptJan 31, 2023
- Sellas Life Sciences Group Inc Galinpepimut-S Update Call TranscriptNov 14, 2022
- Sellas Life Sciences Group Inc Galinpepimut-S Update Call TranscriptSep 15, 2022
- Sellas Life Sciences Group Inc Provides Business Update and First Quarter 2022 Highlights TranscriptApr 06, 2022
- Sellas Life Sciences Group Inc Virtual Investor Symposium Corporate Call TranscriptAug 17, 2021
- Sellas Life Sciences Group Inc Shareholder Update Call TranscriptJun 03, 2021
- Sellas Life Sciences Group Inc Annual Shareholders Meeting TranscriptJun 09, 2020
- Sellas Life Sciences Group Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Sellas Life Sciences Group Inc Corporate Analyst Meeting TranscriptNov 15, 2019
Sellas Life Sciences Group Inc Virtual Investor Symposium Corporate Call Transcript
Good morning or good afternoon, everyone. Giving the platform a moment for everyone to join. I see the number is getting higher right now. Okay. So I'm going to kick it off now that we have a lot of people. I'm Allison Soss from KCSA Strategic Communications, and I would like to welcome you all to the SELLAS Investor symposium on GPS.
Before we begin, I would like to remind you that SELLAS will be making statements on today's call relating to future expectations regarding the further development of and regulatory plans for GPS. These statements constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. And, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the company's clinical plans, risks and uncertainties associated with immunotherapy product development and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)